Takeda sells more non-core assets for $322 million

21 December 2020

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has signed an agreement to divest a portfolio of five select non-core prescription pharmaceutical products sold in China to Chinese firm Hasten Biopharmaceutic.

Takeda will receive $322 million, subject to customary legal and regulatory closing conditions. Under the terms of the deal, Hasten will acquire the rights, title and interest to the products in the portfolio exclusive to China.

The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China. The portfolio generated fiscal year 2019 net sales of approximately $109.5 million, driven by strong sales of cardiovascular products such as Ebrantil (urapidil). While the products included in the sale continue to play important roles in meeting patient needs in the country, they are outside of Takeda's chosen business areas – gastroenterology (GI), rare diseases, plasma-derived therapies, oncology and neuroscience – that are core to its global long-term growth strategy.

Now exceeds divesture target

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK